Journal article · 2026 · Open access
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
New England Journal of Medicine · Published 1 October 2026 · DOI 10.1056/nejmoa2607219
In brief
“Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes” is a 2026 journal article by Sean Wharton and 30 co-authors, published in New England Journal of Medicine. OpenAlex counts 8 citations as of 16 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY-SA licence: the full text is free to read at ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam).
- Citations
- 8
- Most cited in
- 2026 (8)
- Field-weighted impact
- 27.98
- References
- 36
- Authors
- 31
Abstract
BACKGROUND: For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational glucagon receptor-GLP-1 receptor dual agonist with potential weight-reducing and metabolic benefits. METHODS: In this multinational, double-blind, phase 3 trial involving adults with type 2 diabetes and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 27 or more, we randomly assigned participants in a 1:1:1 ratio to receive once-weekly subcutaneous survodutide (3.6 mg or 6.0 mg) or placebo. The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76. RESULTS: Among 752 participants (250 in the 3.6-mg survodutide group, 251 in the 6.0-mg survodutide group, and 251 in the placebo group), the mean age at baseline was 55.7 years, and the mean BMI was 36.5; 49.3% were men. The mean weight change at week 76 according to the treatment-regimen estimand (which assessed effects regardless of whether the trial regimen was discontinued or interrupted or whether other antiobesity therapies were used) was -8.2% (95% confidence interval [CI], -9.2 to -7.2) in the 3.6-mg group, -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mg group, and -3.9% (95% CI, -4.9 to -2.9) in the placebo group; weight reduction of at least 5% occurred in 57.6%, 64.5%, and 35.1% of the participants, respectively (P<0.001 for all comparisons with placebo). The mean change in the glycated hemoglobin level (from a baseline level of 7.4%) was -0.9 percentage points in the 3.6-mg group, -0.8 percentage points in the 6.0-mg group, and -0.2 percentage points in the placebo group. The most common adverse events were gastrointestinal (generally mild to moderate and transient), which occurred in 182 participants (72.8%) in the 3.6-mg group, 195 (77.7%) in the 6.0-mg group, and 97 (38.6%) in the placebo group. CONCLUSIONS: In adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo. (Funded by Boehringer Ingelheim; SYNCHRONIZE-2 ClinicalTrials.gov number, NCT06066528.).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wharton, S., le Roux, C. W., Startseva, E., Kloer, I. M., Alhussein, A., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., Butt, J. H., Ekinci, E. I., Jastreboff, A. M., Ji, L., Schou, M., Tinahones, F. J., Kokkinos, A. D., Merkely, B. P., . . . Kaplan, L. M. (2026). Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2607219
MLA 9
Wharton, Sean, et al. “Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2607219.
Chicago
Wharton, Sean, Carel Wynand le Roux, Elena Startseva, Isabel M. Kloer, Ahmad Alhussein, Samina Ajaz Hussain, Anna Unseld, et al. 2026. “Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2607219.
Harvard
Wharton, S. et al. (2026) ‘Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes’, New England Journal of Medicine. doi:10.1056/nejmoa2607219.
IEEE
S. Wharton et al., “Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2607219.
BibTeX
@article{wharton2026survodutide,
title = {{Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes}},
author = {Wharton, Sean and le Roux, Carel Wynand and Startseva, Elena and Kloer, Isabel M. and Alhussein, Ahmad and Hussain, Samina Ajaz and Unseld, Anna and Bozkurt, Biykem and Ard, Jamy D. and Bays, Harold Edward and Bogdański, Paweł and Butt, Jawad H. and Ekinci, Elif Ilhan and Jastreboff, Ania M. and Ji, Linong and Schou, Morten and Tinahones, Francisco José and Kokkinos, Alexander D. and Merkely, Béla Péter and Ogawa, Wataru and Pedersen, Sue D. and Pietiläinen, Kirsi Hannele and Quinn, Dean and Sattar, Naveed A. and Seufert, Jochen and Stenlöf, Kaj and van Beek, André P. and Vangoitsenhoven, Roman and Brueckmann, Martina and Younes, Ramy and others},
journal = {New England Journal of Medicine},
year = {2026},
doi = {10.1056/nejmoa2607219},
url = {https://doi.org/10.1056/nejmoa2607219}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- survodutide
- type 2 diabetes
- obesity
- weight loss
- HbA1c
- glycemic control
- subcutaneous administration
- weekly dosing
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Wharton, S., le Roux, C. W., Startseva, E., Kloer, I. M., Alhussein, A., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., Butt, J. H., Ekinci, E. I., Jastreboff, A. M., Ji, L., Schou, M., Tinahones, F. J., Kokkinos, A. D., Merkely, B. P., . . . Kaplan, L. M. (2026). Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2607219
How many times has this paper been cited?
8 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam): sign in and open the full text from this page.
Who wrote this paper?
Sean Wharton, Carel Wynand le Roux, Elena Startseva, Isabel M. Kloer, Ahmad Alhussein, Samina Ajaz Hussain, Anna Unseld, Biykem Bozkurt, Jamy D. Ard, Harold Edward Bays, Paweł Bogdański, Jawad H. Butt and 19 more.
What is the DOI of this paper?
10.1056/nejmoa2607219, permanently at https://doi.org/10.1056/nejmoa2607219. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.